We elucidate that an underappreciated function of truncated APC in CRC is its ability to drive an immunosuppressive program that boosts tumor progression. Our work could provide a new perspective for the clinical application of immunotherapy in patients with CRC resistant to ICB therapy.

16 days ago

Journal • IO biomarker

HIF1A (Hypoxia inducible factor 1, alpha subunit) • APC (APC Regulator Of WNT Signaling Pathway) • METTL3 (Methyltransferase Like 3)

APC mutation • HIF1A expression

onvatilimab (CI-8993)

5ms

Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993. (PubMed, Eur J Nucl Med Mol Imaging)

We radiolabelled and validated [89Zr]Zr-Df-CI-8993 for specific binding to huVISTA in vivo. Our results demonstrate that 89Zr-labelled CI-8993 is now suitable for targeting and imaging VISTA expression in human trials.

5 months ago

Journal

VSIR (V-Set Immunoregulatory Receptor)

onvatilimab (CI-8993)

1year

CI-8993-101: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)

P1, N=26, Completed, Curis, Inc. | Active, not recruiting --> Completed

1 year ago

Trial completion • Metastases

onvatilimab (CI-8993)